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Abstract 
Background 
Queensland, Australia has the highest rates of cutaneous squamous cell carcinoma (SCC). 
Perineural invasion (PNI) is associated with reduced local control and survival.  
 
Methods 
A retrospective review of a prospective database of patients with clinical PNI from cutaneous 
SCC of the head and neck (CSCCHN) treated with surgery and post-operative radiotherapy 
between 2000-2011 and a minimum of 24 months follow-up. Patients were excluded if 
immunosuppressed, had non-SCC histology or treated palliatively.  
 
Results 
50 patients (mean age 60 years) with median follow-up of 50 months were included. 54.8% of 
known primary tumors had incidental PNI. 10% had nodal disease at presentation. MR 
neurogram was positive in 95.8%. Recurrence-free survival at 5-years was 62%. 5-year 
disease-specific survival and overall survival were 75% and 64%, respectively. There were no 
peri-operative deaths.  
 
Conclusion 
This report demonstrates that long-term survival is achievable in patients with clinical PNI 
from CSCCHN following surgery and post-operative radiotherapy.  
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Introduction 
Cutaneous squamous cell carcinoma of the head and neck (CSCCHN) occurs at epidemic 
rates in Australia.1 Perineural invasion (PNI) is defined as the presence of tumor cells in the 
perineural space of a peripheral nerve and is estimated to occur in less than 5% of CSCCHN 
cases. When PNI is asymptomatic and only detected on histology, it is known as incidental 
PNI. When there is spread of tumor along the perineural space of a nerve, this is termed 
clinical PNI or perineural spread (PNS). This may manifest radiologically, histologically or 
clinically with progressive symptoms and signs of nerve dysfunction in the distribution of the 
affected nerve (i.e. dysaesthesia, facial palsy). The presence of perineural spread and its 
extent is best assessed by magnetic resonance (MR) neurography, preferably using a 3.0 
Tesla (3T) platform.2 
 
Clinical PNI is associated with higher rates of local recurrence and reduced overall survival 
when compared to incidental PNI.3,4 The nerves most commonly affected are the trigeminal 
(V1 ophthalmic, V2 maxillary and V3 mandibular divisions) and facial (VII) cranial nerves. PNS 
along a peripheral nerve is contiguous, and is primarily retrograde (towards the brainstem) yet 
can be antegrade (towards the skin). Skip lesions (if seen) are likely the result of technical 
processing artifact and not tumor emboli.5,6 In addition, perineural invasion with concomitant 
intraneural invasion is seen in the majority of cranial nerve pathological specimens.6 The 
natural history of PNS is typically slow retrograde tumor spread toward the brainstem with 
poor prognosis (i.e. central failure).  
 
The American Joint Committee on Cancer (AJCC; 2010 7th edition) classifies all PNI into the 
skull base as T4 disease.7 Currently, no consideration is given to the precise zonal extent of 
PNS, which has been shown to influence patient outcome.8 Zonal extent of cranial nerve PNS 
is used at our institution for classification (see Table 1).9 Generally, zone 1 or 2 disease is 
operable, whilst zone 3 disease is considered not, due to the perceived higher risk of 
iatrogenic spread of tumor via the cerebrospinal fluid (CSF) during surgery. However, surgery 
is considered on a case-by-case basis. 
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The management of clinical PNI varies between institutions yet surgical resection followed by 
post-operative radiotherapy (PORT) can lead to improved patient outcomes in selected 
patients.10 Previously reported outcome data is restricted in its clinical application through the 
use of varying treatment approaches,3,11 and pooling of either incidental PNI and clinical PNI 
cohorts12 or different tumor types (i.e. SCC and basal cell carcinoma, BCC).4 The purpose of 
this study is to describe the long-term survival of patients with perineural spread from 
CSCCHN treated with surgery and post-operative radiotherapy.  
 
Materials and Methods 
50 consecutive patients with clinical PNI from CSCCHN treated with curative intent surgery 
between 2000-2011 with a minimum 24 months follow-up for alive patients identified from a 
prospective database were included. Immuno-suppressed patients (n = 2) and patients with 
PNI of other tumor types (melanoma {n = 2} and BCC {n = 6}) were excluded. Informed 
patient consent and ethics approval from the Metro South Human Research Ethics 
Committee was obtained (2003/197). Details of primary tumors were obtained from pathology 
archives. Primary tumors and perineural spread was classified according to AJCC 2010 TNM 
criteria (see Tables 2 and 3).7 An ‘r’ notation was applied to the staging if a patient presented 
with PNS from recurrence of a previously treated primary skin cancer.  
 
All patients underwent pre-operative diagnostic imaging with MR neurography evaluated by a 
skull base radiologist, or computed tomography (CT) when MRI was contraindicated. All 
management plans were discussed in specialized multidisciplinary head and neck and/or 
skull base tumor boards. Surgical resection was planned with imaging findings and all tumors 
were resected en bloc with frozen section margin control via a skull base or sub-cranial 
approach as described in Table 4 and in our previous reports.6,10,13 Surgery was of curative 
intent in all patients. Neck dissection was performed if: (i) nodal disease was evident or 
suspected on pre-operative assessment; or (ii) surgical access to the neck was required to 
enable reconstruction.  
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PORT was offered to all eligible patients. Treatment was individualized depending on each 
patient’s suitability and disease extent (skin, nerve, nodal involvement). In the later half of the 
2000’s, prescribed volumes were typically dependent on the zonal extent of disease on 
imaging and pathology: zone 1 up to ganglion; zone 2 to the pre-pontine aspect of the nerve; 
and zone 3 up to brainstem.9 Fields encompassed the peripheral branches of involved 
nerves, and the regional nodes were addressed only if pathologically involved. Bolus was 
generally considered over the skin corresponding with the nerve distribution. Post-operative 
concurrent chemo-radiotherapy was only used if extra-capsular nodal extension was present.  
 
Post-operative follow-up consisted of regular outpatient review (quarterly until 3 years, then 
biannually until at least 5 years post-treatment) in conjunction with baseline and serial MR 
neurography for surveillance (biannually until 3 years, then annually to 5 years). Follow-up 
was taken from the date of surgery until date of last follow-up or date of death. Recurrence 
was classified as local (further sub-classified as peripheral at skin or central at meninges/ 
brain/brainstem), regional (nodal) or distant metastasis. Local recurrence was defined as 
either an in-field, or out-field of radiotherapy.  
 
The primary outcomes measured were loco-regional control (LRC), recurrence-free survival 
(RFS, any recurrence), disease-specific survival (DSS, death from disease) and overall 
survival (OS, death from all causes). Variables assessed included age, gender, nodal 
involvement, nerve(s) involved, single/multiple nerves involved, disease zone, margin status, 
PORT, salvage versus definitive intent and tumor differentiation. Since there were only two 
patients with zone 3 disease, zone 2 and 3 were combined for analysis. Crude survival 
probabilities were estimated and plotted using the Kaplan-Meier technique and analysis 
undertaken to assess for significant associations with the variables detailed above. A p value 
of ≤ 0.05 was deemed statistically significant. Analyses were conducted using SAS software 
Version 9.2 (SAS Institute Inc. Cary, NC).  
 
Results 
Patient and primary tumor characteristics 
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Patient and primary tumor characteristics are described in Table 2. Mean age at the start of 
treatment for clinical PNI was 60 years (range 34-91 years), and the overall male-to-female 
ratio was approximately 4:1. Median follow-up period following surgery was 50 months (range 
9-151 months).  
 
All tumors with PNS to the skull base are staged as T4 however as most cases present some 
time after the primary has been excised we assessed the primary cutaneous SCC. Of these, 
60% had an obvious primary and the majority were staged as T2 (40%, 20/50). 12% of 
patients presented with PNS having had no cutaneous primary tumor (6/50, T0). In 28% of 
patients the primary tumor was unassessable (TX) due to either: (i) incomplete/missing 
pathology reports or cutaneous malignancies treated externally without formal histological 
diagnosis (i.e. cryotherapy, laser or shave excision through primary care provider); or (ii) the 
exact primary index lesion was uncertain as multiple cutaneous malignancies were present in 
the region of interest.  
 
The frequencies of all known primary sites are detailed in Table 2. The cheek was the most 
common location of a cutaneous primary (20%). In 28% of patients, the location of the 
primary was unknown yet the approximate location of certain TX primary tumors was known 
and therefore included. Of the patients treated with surgery for the primary tumor (34 
patients), 12 had involved margins, 8 had close margins, 11 had clear margins and 3 had 
unclear margin status. Of the patients with a known primary tumor, 63.3% had incidental PNI 
reported. From the histopathology reports of primary tumors that included a measurement of 
involved nerve diameter (n = 12), the maximal diameter ranged from 0.03 mm – 0.9 mm 
(median 0.2 mm).   
 
Assessment 
The features of perineural spread are described in Table 3. MR neurogram was performed in 
96% (48/50) and was positive for PNS in 95.8% (46/48). Two patients were assessed with 
computed tomography only (CT) due to MRI contra-indications, and this was positive in one 
patient. All patients with clinically evident PNS of the trigeminal nerve at presentation had 
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disease evident on MR neurography (43/43). The extent of PNS was zone 1 in 32% (16/50), 
zone 2 in 60% (30/50) and zone 3 in 4% (2/50). Spinal nerve involvement is rare and not 
currently represented in the zonal classification system. Two patients with great auricular 
nerve involvement are included in this series. 
 
There were two patients with negative MR neurography. One patient, who had a pre-auricular 
SCC with incidental PNI previously treated with surgery and post-operative radiotherapy, 
presented with a partial facial nerve palsy and no detectable PNS on MR neurography. The 
facial nerve branch was 0.5 mm diameter on histopathology. The second patient presented 
with a parotid mass and local dysaesthesia, and a past history of a cheek SCC. Great 
auricular nerve PNS was detected intra-operatively and confirmed on histopathology (nerve 
diameter 1 mm), yet disease was not detectable on MR neurography.  
 
94% of patients were clinically staged as N0 at presentation. 4% (2/50) were staged N1 and 
2% (1/50) staged N2 pathologically. All patients were classified as M0. Eighteen patients 
(36%) presented with a subcutaneous tumor mass overlying or adjacent to the involved 
cranial nerve exit foramina. The majority of these were in the V1 or V2 distribution yet masses 
were also detected under the pre-auricular skin. 
 
Treatment 
All patients underwent en-bloc surgical resection of involved nerve(s) with curative intent (for 
approaches see Table 4).6,10,13 28% received prior treatment for perineural spread (surgery 
and/or radiotherapy) and were treated as salvage intent in this series. 5 patients (10%) 
underwent a neck dissection: 3 for apparent clinical N1 disease or greater (confirmed 
pathologically); 1 to permit access for reconstruction (N0); and 1 due to clinical suspicion 
(clinical N0, pathological N2b). 32% (16/50) of patients required an orbital exenteration for V1 
involvement.  
 
There were no peri-operative deaths. Surgical complications included: free-flap failure 
requiring return to theatre (n = 1), deep-vein thrombosis (n = 1), extradural hemorrhage 
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requiring evacuation in theatre (n = 1), CSF leak treated with lumbar drain (n = 1), and wound 
infection (n = 1) treated with washout and antibiotics. In addition, one patient sustained an 
intra-operative myocardial infarction necessitating a change in reconstruction plan 
(undertaken with local flap instead of free flap). This patient developed peri-operative 
pneumocephalus and a CSF leak with poor neurological recovery requiring rehabilitation, and 
subsequently died from pneumonia 9 months post-treatment. Also, one patient developed an 
oro-antral fistula after a sub-labial approach to V2 and PORT, and had successful local flap 
repair.  
 
Clear central nerve margin was obtained in 35 patients (70%), and 5 patients (10%) had close 
margins (i.e. < 5 mm clearance). Two patients required a two-stage operation to clear a nerve 
margin, whilst one patient required a three-stage operation. Clearance of potential peripheral 
nerve margin in skin was not pursued due to the risk of disfigurement, and PORT was relied 
upon for treatment of potential peripheral nerve distribution spread.  
 
The detail of nerves involved is included in Table 3. V2 was the most common nerve (42%), 
followed by V1 (36%) and VII (36%). The majority of patients had single nerve involvement 
(68%). Multiple nerve involvement occurred in 32%, with the most common scenario being VII 
and V3 co-involvement. The great auricular nerve (C2 spinal nerve) was involved in 2 patients, 
with disease peripheral to the dorsal root ganglion.  
 
94% (47/50) received PORT with dose range of 50-63 Gray in 25-30 fractions daily 5 
days/week. Five patients received nodal irradiation for regional nodal disease present on 
histopathology, and five patients elective nodal irradiation. Two patients who failed previous 
definitive RT were treated with salvage surgery and not offered further PORT. One died from 
disease after local recurrence 53 months post-treatment, and the other remains disease free 
75 months post-treatment. One further patient with zone 1 disease initially not offered PORT 
due to age (91 years), subsequently developed subcutaneous peripheral recurrence 7 
months later which was treated with salvage surgery and local PORT. This patient remains 
disease free 30 months since last treatment. Complications following PORT included wound 
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breakdown (n = 2), radionecrosis (n = 4; 3 affecting bone, 1 affecting anterior temporal lobe), 
corneal irritation necessitating orbital exenteration (n = 2) and visual impairment (radiation 
microangiopathy, n = 2) treated conservatively. One patient received chemotherapy (cisplatin) 
for nodal disease with extra-capsular extension.   
 
Outcomes 
OS at 5-years was 64% with 14 deaths in this series (see Figure 1). 10 patients died from 
disease, with DSS at 5-years of 75% (see Figure 2). Mean time to death from disease was 39 
months (range 10-90 months; median 30 months). The ultimate cause of death was 
predominantly central failure (12%), none being in the brainstem, with composite peripheral 
failure in 4% and distant metastasis in 4% (see Table 5).  
 
Patterns of recurrence are described in Table 5. RFS at 5-years was 62% (see Figure 3). 
There were 18 patients with recurrence of disease, and 6 patients had a second recurrence. 
Mean time to any recurrence was 24 months (range 4-75 months; median 21 months), with 
81% occurring within 4 years and 95% within 5 years post-treatment. Recurrence was 
significantly associated with worse OS (p = 0.002). Local recurrence was the most common 
pattern, particularly peripheral in-field (14%). Three patients had central recurrence of disease 
(two with simultaneous peripheral and central recurrence), and all died from disease. One 
patient recurred with regional nodal disease (on the outer edge of the treatment field) and one 
recurred with local, regional and distant disease.  
 
LRC at 5-years was 62% (see Figure 4), and successful surgical salvage of loco-regional 
recurrence was achieved in 33% (6/18). Two patients had out-of-field local recurrence on the 
contralateral side with eventual central failure (one at 75 months post-treatment, possibly 
representing a second yet unknown primary). One patient developed out-of-field loco-regional 
recurrence at 20 months post-surgery in the distal branches of V2 and V3, and following 
salvage surgery remains alive and disease-free at 118 months since last treatment.  
 
This article is protected by copyright. All rights reserved.
RFS at 5-years by zonal disease extent demonstrated a significant difference when zone 1 
(88%) was compared to zone 2 and 3 combined (51%, p = 0.05, see Figure 5). DSS at 5-
years by zonal disease extent was 93% for zone 1 disease and 73% for zone 2 and 3 
combined (p = 0.17). OS at 5-years by zonal disease extent was 75% for zone 1 disease and 
63% for zone 2 and 3 combined (p = 0.2). Age, gender, nodal involvement, nerve involved, 
single versus multiple nerves involved, PORT, salvage versus definitive intent, and tumor 
differentiation were not associated with recurrence or survival. Margin status did not 
demonstrate a significant association with recurrence or survival, yet a trend towards 
significantly better overall survival was evident when patients with clear/close margins were 
compared to those with involved margins (p = 0.13; see Figure 6). 
 
Discussion 
This case series details the outcomes of patients with perineural spread from CSCCHN 
treated with surgery and PORT. This treatment approach offers patients a reasonable survival 
benefit with a limited rate of complications. This is contingent on careful pre-operative 
planning, including appropriate imaging, and treatment within a specialized multidisciplinary 
unit.  
 
The most common location of primary tumor was the cheek, and V2 disease extending to 
zone 2 is the most common site and extent of clinical PNI. Almost 40% of known primary 
tumors did not demonstrate PNI, and this may reflect the inherent difficulties in detecting PNI 
in an asymptomatic patient.14 Importantly, the absence of either PNI in a primary tumor or an 
obvious index lesion does not exclude a patient from having clinical PNI, and can lead to 
diagnostic delays as the symptoms and signs may be wrongly attributed to Bell’s palsy or 
trigeminal neuralgia.15  
 
The prognostic significance of nerve diameter in the primary tumour remains unclear, yet it 
has been proposed that a diameter ≥ 0.1 mm is associated with aggressive disease.16,17 
Standardized pathology reporting to include all high-risk features of cutaneous malignancies 
is important to permit accurate staging of each primary and to guide appropriate adjuvant 
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treatment. Only 12/30 pathology reports of primary tumours included an involved nerve 
diameter measurement (median 0.2 mm; range of 0.03 - 0.9 mm), and robust analysis in this 
study is therefore not possible. 
 
MR neurography compliments all aspects of patient management from diagnosis and 
treatment planning through to follow-up and surveillance. MR neurography is useful for 
disease staging with the zonal classification system, which in turn guides surgical planning 
and resection extent and should be offered to all eligible patients. Of note, all patients in this 
series with V nerve involvement had positive MR neurography. The two cases in this series 
with MR-negative disease represented either rare disease (one patient with great auricular 
nerve involvement) or early disease (one patient with partial VII involvement in a previously 
irradiated parotid bed).  
 
Some centers report imaging-negative PNS at rates of 22-47% and this may reflect the use of 
unfocussed whole-brain MRI or an absence of disease.3,18 In our experience imaging-negative 
disease in a symptomatic patient is uncommon as evidenced by 94% of patients in this series 
being imaging-positive. This is enhanced with the use of 3T MRI with neurography protocol 
interpreted by a skull base radiologist, with 95.8% being positive. Imaging-positive disease in 
an asymptomatic patient is rare, and may warrant nerve biopsy prior to large-scale resection. 
CT or CT/PET imaging is recommended if MRI is contra-indicated but lacks sensitivity.  
 
The rate of regional nodal involvement in patients with clinical PNI is estimated at 
approximately 9-16%.4,11,19 The rate of regional nodal disease in this series was low at 10%, 
and only two patients had regional nodal recurrence (one as first recurrence, one as a second 
recurrence). This is consistent with the premise that PNS is likely a function of both tumor 
biology and proximity to nerve, and is a unique form of metastasis largely independent of 
lymphatic metastasis. Some centers advocate elective nodal irradiation due to a risk of 
subclinical disease.20 Presently at our institution, nodal irradiation is generally only offered if 
nodal disease is evident clinically or pathologically. A neck dissection would be undertaken 
for the same reason, or if required for reconstruction.  
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 Surgical resection for perineural spread is typically only undertaken with curative intent and 
the surgical approach to PNS is dictated by the nerve(s) involved as outlined in Table 4.13 
This is followed by PORT in all eligible patients. Surgery is offered to patients with zone 1 and 
zone 2 disease, whilst surgery for zone 3 disease is considered on a case-by-case basis. 
Resection of bulky zone 3 disease has the potential to cause tumor seeding and 
dissemination via the CSF and at our institution patients with zone 3 disease are generally 
offered radical or palliative radiotherapy.  
 
Complications from surgery were limited and related to the large-scale nature of the surgery 
required for disease clearance. Importantly, there were no peri-operative deaths. 
Radiotherapy was also associated with limited treatment effects, however two patients 
required an orbital exenteration for delayed eye complications (prior to the use of IMRT). At 
our institution, it is now largely routine to undertake an orbital exenteration for V1 disease 
approximately 1 cm beyond the supraorbital notch. This is not only performed for disease 
clearance, but also since the sequelae from the necessary PORT to the globe are severe. In 
patients with V2 and/or V3 involvement requiring ganglion resection, an attempt is made to 
preserve corneal sensation by preserving the V1 component of the ganglion. However, in 
those patients where the whole ganglion was resected to obtain a clear margin, no patient 
subsequently experienced ophthalmic issues necessitating ongoing management.  
 
A summary of recent outcome data for imaging positive disease is outlined in Table 6. 
Previous studies have limited applicability as many have heterogeneous patient cohorts 
treated with different modalities.3,4,11,12 This series demonstrates that long-term survival is 
achievable in patients treated with appropriate surgery and PORT, with almost 65% of 
patients alive at 5 years. Improved outcomes including 75% survival from disease at 5 years 
are evident, compared to previous reports of 58-65% in patients with BCC and SCC receiving 
radiotherapy with limited surgery.4,19 Similarly, when compared to another series with a similar 
patient cohort from the state of Queensland and limited surgery, RFS was 62% in our series 
compared to 39%.11  
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 The median time to death from disease in this series was 30 months. One patient died from 
contralateral spread of disease at 90 months follow-up, 15 months after it was detected. This 
reflects the often slow spreading nature of PNS, and the inherent ability of tumor to spread to 
contralateral nerve branches.21 Local recurrence is the most common mode of treatment 
failure. 95% of all recurrences occurred within 5 years of treatment, reiterating the need for 
long-term follow-up. At our institution, patients are followed up for at least 5 years.  
 
Recurrence was also noted to be significantly associated with worse overall survival outcome. 
This reflects both aggressive tumor biology and the limitations in salvage options following 
treatment failure, however up to a third of patients were salvaged with surgery in this series. 
Of the 3 patients who recurred centrally none occurred in the brainstem, suggesting that the 
central spread of disease was controlled by appropriate surgery and targeted PORT. The 
zonal extent of disease was shown to be significantly associated with risk of recurrence, with 
RFS at 5-years of 88% in zone 1 and 51% when zone 2 and 3 were combined. These 
findings demonstrate that improved disease control can be achieved with timely diagnosis 
and management.  
 
Conclusion 
This case series demonstrates improved outcomes with relatively low morbidity for patients 
with CSCCHN with clinical PNI treated with surgical resection and PORT. Careful surgical 
candidate selection, pre-operative planning with MR neurography and management through a 
specialized multidisciplinary team is recommended. Early intervention is paramount and 
dependent on a timely diagnosis, and this is expected to improve with advancing imaging 
technology and increasing clinician and patient awareness of this disease. 
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Figure legends 
Figure 1. Kaplan-Meier curve of overall survival for patients with perineural spread from 
cutaneous SCC treated with surgical resection and post-operative radiotherapy.  
 
Figure 2. Kaplan-Meier curve of disease-specific survival for patients with perineural spread 
from cutaneous SCC treated with surgical resection and post-operative radiotherapy.  
 
Figure 3. Kaplan-Meier curve of recurrence-free survival for patients with perineural spread 
from cutaneous SCC treated with surgical resection and post-operative radiotherapy.  
 
Figure 4. Kaplan-Meier curve of locoregional control for patients with perineural spread from 
cutaneous SCC treated with surgical resection and post-operative radiotherapy. 
 
Figure 5. Kaplan-Meier curve of recurrence-free survival by zonal disease extent for patients 
with perineural spread from cutaneous SCC treated with surgical resection and post-operative 
radiotherapy (p= 0.05). Zone 1 has been compared to Zone 2 and Zone 3. 
 
Figure 6. Kaplan-Meier curve of overall survival for patients with perineural spread from 
cutaneous SCC treated with surgical resection and post-operative radiotherapy by margin 









Figure 1  
309x220mm (72 x 72 DPI)  
 
 
Page 18 of 29
John Wiley & Sons, Inc.
Head & Neck




Figure 2  
319x229mm (72 x 72 DPI)  
 
 
Page 19 of 29
John Wiley & Sons, Inc.
Head & Neck




Figure 3  
317x228mm (72 x 72 DPI)  
 
 
Page 20 of 29
John Wiley & Sons, Inc.
Head & Neck




Figure 4  
306x217mm (72 x 72 DPI)  
 
 
Page 21 of 29
John Wiley & Sons, Inc.
Head & Neck




Figure 5  
295x209mm (72 x 72 DPI)  
 
 
Page 22 of 29
John Wiley & Sons, Inc.
Head & Neck




Figure 6  
275x177mm (72 x 72 DPI)  
 
 
Page 23 of 29
John Wiley & Sons, Inc.
Head & Neck




Table 1  
297x209mm (150 x 150 DPI)  
 
 
Page 24 of 29
John Wiley & Sons, Inc.
Head & Neck





209x297mm (150 x 150 DPI)  
 
 
Page 25 of 29
John Wiley & Sons, Inc.
Head & Neck




Table 3  
209x297mm (150 x 150 DPI)  
 
 
Page 26 of 29
John Wiley & Sons, Inc.
Head & Neck




Table 4  
209x297mm (150 x 150 DPI)  
 
 
Page 27 of 29
John Wiley & Sons, Inc.
Head & Neck




Table 5  
297x209mm (150 x 150 DPI)  
 
 
Page 28 of 29
John Wiley & Sons, Inc.
Head & Neck




Table 6  
297x209mm (150 x 150 DPI)  
 
 
Page 29 of 29
John Wiley & Sons, Inc.
Head & Neck
This article is protected by copyright. All rights reserved.
